Breast Cancer Therapeutics in Major Developed Markets Trends to 2021 2 | Page 5

4.3 Competitive Clinical Trials Metrics Analysis 52
5 Promising Drug Candidates in Pipeline 54
5.1 Abemaciclib – Eli Lily 54
5.1.1 Abemaciclib Forecast 54
5.2 Buparlisib – Novartis 55
5.2.1 Buparlisib Forecast 56
5.3 NeuVax (nelipepimut-S) – Galena Biopharma 56
5.3.1 NeuVax Forecast 57
5.4 Niraparib – Tesaro 57
5.4.1 Niraparib Forecast 58
5.5 Lynparza (Olaparib) – AstraZeneca 58
5.5.1 Lynparza Forecast 59
5.6 Veliparib – AbbVie 60
5.6.1 Veliparib Forecast 60
5.7 Neratinib – Puma Biotechnology 61
5.7.1 Neratinib Forecast 62
5.8 Ribociclib – Novartis 62
5.8.1 Ribociclib Forecast 63
5.9 Talazoparib – BioMarin 64
5.10 Alpelisib – Novartis 64
5.11 Atezolizumab – Roche 65
5.12 Entinostat – Syndax 65
5.13 Margetuximab – MacroGenics 66
5.14 Taselisib – Genentech 67
5.15 OBI-822/821 – OBI Pharma 68